Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

QIAstat-Dx Gl panel study results

December 2019—Qiagen announced the publication of a multicenter clinical study demonstrating the accuracy of its QIAstat-Dx syndromic testing solution for diagnosing the causes of acute gastroenteritis.

The study evaluated 385 patient samples at university hospital laboratories across Europe and showed the QIAstat-Dx Gastrointestinal Panel was highly sensitive (98.2 percent positive) and specific (99.9 percent negative). Multiple pathogens were identified in nearly one-third of the patient samples that tested positive. The study also cited the ability of the panel to provide cycle threshold values and amplification curves to aid in interpreting results.

Roche launches Cobas EBV, BKV tests

December 2019—Roche announced the commercial availability of the Cobas EBV (Epstein-Barr virus) and Cobas BKV (BK virus) tests for use on the Cobas 6800/8800 systems in countries accepting the CE mark. The tests are used to assess if transplant patients are at risk of developing disease by these pathogens, which can contribute to organ rejection.

Keytruda combo gets accelerated approval

December 2019—The Food and Drug Administration granted accelerated approval to the combination of pembrolizumab (Keytruda, Merck) plus lenvatinib (Lenvima, Eisai) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high or mismatch repair deficient and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

MilliporeSigma acquires FloDesign Sonics

December 2019—MilliporeSigma has acquired FloDesign Sonics, Wilbraham, Mass., developer of an acoustic cell processing platform for cell and gene therapy manufacturing.

Direct HbA1c testing in whole blood

December 2019—The Randox RX series provides laboratories with the capabilities of onboard HbA1c testing in whole blood on three fully automated RX analyzers—RX Modena, RX Imola, and RX Daytona+ —to accommodate rapid and reliable measurement of HbA1c in different laboratory settings.

T2Resistance Panel available as RUO test

December 2019—T2 Biosystems announced that its T2Resistance Panel is available as a research use only test in the United States. The panel is expected to receive the CE mark by the end of 2019.

Hematogenix BCMA flow cytometry, IHC assays

December 2019—Hematogenix announced the availability of the assessment of B-cell maturation antigen by flow cytometry and immunohistochemistry at its facilities in China, Asia, Europe, and the United States.

High-yield liquid biopsy sample prep platform

December 2019—nRichDX introduced its Revolution System, a high-yield sample prep platform designed to increase liquid biopsy–based test sensitivity by delivering more target input for molecular assays. The target yield increase is accomplished by combining the ability to process a range of sample volumes (3–50 mL) with recovery rates of 70–90 percent.

Capmatinib designated as breakthrough therapy

December 2019—The FDA granted breakthrough therapy designation to Novartis’ capmatinib (INC280) as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer.

Ortho Clinical expands testing menu

December 2019—Ortho Clinical Diagnostics, in collaboration with Thermo Fisher Scientific, has expanded the menu on MicroTip-capable Vitros systems to enable testing for fentanyl and tricyclic antidepressants.

MARKETPLACE

TRENDING